Literature DB >> 30891128

Second Generation Inhibitors of HIV-1 Maturation.

Alicia Regueiro-Ren1, Ira B Dicker2, Umesh Hanumegowda2, Nicholas A Meanwell3.   

Abstract

The strategy and tactics subtending the discovery and development of the second generation HIV-1 maturation inhibitor GSK-3532795/BMS-955176, a compound that exhibits a broader spectrum of antiviral effect in vitro and in clinical studies than the prototypical maturation inhibitor bevirimat, are described.

Entities:  

Year:  2019        PMID： 30891128      PMCID： PMC6421530          DOI： 10.1021/acsmedchemlett.8b00656

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


  41 in total

1.  The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Ferri Soheilian; Kunio Nagashima; Eric O Freed
Journal:  Virology       Date:  2010-02-20       Impact factor: 3.616

2.  Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1.

Authors:  Kurt Van Baelen; Karl Salzwedel; Evelien Rondelez; Veerle Van Eygen; Stephanie De Vos; Ann Verheyen; Kim Steegen; Yvan Verlinden; Graham P Allaway; Lieven J Stuyver
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

3.  Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation.

Authors:  T Kanamoto; Y Kashiwada; K Kanbara; K Gotoh; M Yoshimori; T Goto; K Sano; H Nakashima
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

4.  HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity.

Authors:  Barbara Müller; Maria Anders; Hisashi Akiyama; Sonja Welsch; Bärbel Glass; Krisztina Nikovics; Francois Clavel; Hanna-Mari Tervo; Oliver T Keppler; Hans-Georg Kräusslich
Journal:  J Biol Chem       Date:  2009-08-07       Impact factor: 5.157

5.  Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.

Authors:  Nicolas A Margot; Craig S Gibbs; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

6.  A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle.

Authors:  Sook-Kyung Lee; Janera Harris; Ronald Swanstrom
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

7.  PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.

Authors:  F Li; R Goila-Gaur; K Salzwedel; N R Kilgore; M Reddick; C Matallana; A Castillo; D Zoumplis; D E Martin; J M Orenstein; G P Allaway; E O Freed; C T Wild
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-22       Impact factor: 11.205

Review 8.  Predicting and tuning physicochemical properties in lead optimization: amine basicities.

Authors:  Martin Morgenthaler; Eliane Schweizer; Anja Hoffmann-Röder; Fausta Benini; Rainer E Martin; Georg Jaeschke; Björn Wagner; Holger Fischer; Stefanie Bendels; Daniel Zimmerli; Josef Schneider; François Diederich; Manfred Kansy; Klaus Müller
Journal:  ChemMedChem       Date:  2007-08       Impact factor: 3.466

9.  Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.

Authors:  Patrick F Smith; Abayomi Ogundele; Alan Forrest; John Wilton; Karl Salzwedel; Judy Doto; Graham P Allaway; David E Martin
Journal:  Antimicrob Agents Chemother       Date:  2007-07-16       Impact factor: 5.191

10.  Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation.

Authors:  Jing Zhou; Xiong Yuan; David Dismuke; Brett M Forshey; Christopher Lundquist; Kuo-Hsiung Lee; Christopher Aiken; Chin Ho Chen
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103
View more
  4 in total

1.  In Praise of Remarkably Powerful Centamolecular Therapeutic Agents.

Authors:  Nicholas A Meanwell; William R Ewing
Journal:  ACS Med Chem Lett       Date:  2019-07-18       Impact factor: 4.345

2.  GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile.

Authors:  Ira Dicker; Jerry L Jeffrey; Tricia Protack; Zeyu Lin; Mark Cockett; Yan Chen; Sing-Yuen Sit; Martin Gartland; Nicholas A Meanwell; Alicia Regueiro-Ren; Dieter Drexler; Joseph Cantone; Brian McAuliffe; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2021-11-15       Impact factor: 5.191

3.  Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study.

Authors:  Ira Dicker; Sharon Zhang; Neelanjana Ray; Brett R Beno; Alicia Regueiro-Ren; Samit Joshi; Mark Cockett; Mark Krystal; Max Lataillade
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240

Review 4.  HIV-1 Maturation: Lessons Learned from Inhibitors.

Authors:  Alex B Kleinpeter; Eric O Freed
Journal:  Viruses       Date:  2020-08-26       Impact factor: 5.048
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.